Hi vrs37, looking at the conditions attached to the CE mark I'd be surprised if they get many other sales. The CE limits the use of the product to use in combination with gemcitabine only as a chemotherapy. Gemcitabine alone is a very outdated treatment for this cancer. There are other, more effective chemotherapeutic agents available now, that are likely also reimbursed. So why would an oncologist suggest a patient pay out of their own pocket for a therapy that they know they can get equal or better results from that they don't have to completely cover the cost of.
- Forums
- ASX - By Stock
- OSL
- Ann: OncoSil receives Swiss regulatory approval
OSL
oncosil medical ltd
Add to My Watchlist
5.69%
!
$1.16

Ann: OncoSil receives Swiss regulatory approval, page-47
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M |
Open | High | Low | Value | Volume |
$1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 412 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | 1.160 |
1 | 2126 | 1.150 |
1 | 7500 | 1.080 |
2 | 19761 | 1.050 |
1 | 2500 | 1.030 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 412 | 1 |
1.200 | 8677 | 1 |
1.245 | 2418 | 1 |
1.250 | 46027 | 1 |
1.300 | 1500 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online